Presentation is loading. Please wait.

Presentation is loading. Please wait.

Biomarker introduction Annemieke Aartsma-Rus November 7 2015.

Published byJoanna Fleming Modified over 8 years ago

Similar presentations

Presentation on theme: "Biomarker introduction Annemieke Aartsma-Rus November 7 2015."— Presentation transcript:

1 Biomarker introduction Annemieke Aartsma-Rus November 7 2015

2 What is a biomarker? Annemieke Aartsma-Rus A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention

3 Different types of biomarkers Annemieke Aartsma-Rus Diagnostic biomarkers Something is wrong Prognostic biomarkers Predict disease course mild/severe Therapeutic monitoring biomarkers Predict whether therapy will work/is working Sometimes one biomarker is both diagnostic and prognostic and monitoring but generally NOT

4 Biomarkers used in DMD already Annemieke Aartsma-Rus Diagnostic biomarkers Serum creatine kinase (CK) Elevated in DMD at young age Not disease specific Indication of muscle damage Helps clinicians to make differential diagnosis Gene analysis needed to confirm diagnosis (DMD mutation)

5 Biomarker research for DMD Annemieke Aartsma-Rus Prognostic biomarkers May allow stratification in trials Research ongoing DNA differences (SNPs) in genes involved in inflammation can influence age at loss of ambulation Osteopontin LTBP4 Challenges: Which genes to focus on? Large cohorts needed to confirm findings

6 Biomarker research for DMD Annemieke Aartsma-Rus Therapeutic biomarkers Used for therapeutic monitoring of treatment Identify responders Before trial (more homogeneous population) During trial (to continue with responders) Pharmacodynamic biomarker Surrogate endpoint

7 Biomarker research for DMD Annemieke Aartsma-Rus Pharmacodynamic biomarker Did the treatment work as proposed? Confirmation drug mechanism E.g. dystrophin restoration for exon skipping/ataluren or reduced fibrosis for antioxidant

8 Biomarker research for DMD Annemieke Aartsma-Rus Surrogate endpoints Correlates with clinical benefit (now or in future) A tool that can be used to accelerate the process of making the drug available on the market Advantage: may be quicker and less prone to variation/motivation than functional tests No surrogate endpoint available yet for DMD

Download ppt "Biomarker introduction Annemieke Aartsma-Rus November 7 2015."

Similar presentations

Artesunate Rectal Capsules For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment.

Artesunate Rectal Capsules For the initial management of acute malaria in patients who cannot take medication by mouth and for whom parenteral treatment.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Transforming Correlative Science to Predictive Personalized Medicine Richard Simon, D.Sc. National Cancer Institute

Transforming Correlative Science to Predictive Personalized Medicine Richard Simon, D.Sc. National Cancer Institute
Diagnostics: Patent Eligibility and the Industry Perspective

Diagnostics: Patent Eligibility and the Industry Perspective
© 2006 National Lipid Association Statin Safety: Key Conclusions and Recommendations of the NLA.

© 2006 National Lipid Association Statin Safety: Key Conclusions and Recommendations of the NLA.
Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.

Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
© 2014 SynteractHCR. All rights reserved. SHARED WORK. SHARED VISION. Pitfalls in Companion Diagnostics Don't underestimate the power of conditional probabilities.

© 2014 SynteractHCR. All rights reserved. SHARED WORK. SHARED VISION. Pitfalls in Companion Diagnostics Don't underestimate the power of conditional probabilities.
1 SIMG Florence 4.12.99.ppt The Horizons of Predictive Medicine Dr Ian Gilham Worldwide Director, Predictive Medicine Glaxo Wellcome Research and Development.

1 SIMG Florence ppt The Horizons of Predictive Medicine Dr Ian Gilham Worldwide Director, Predictive Medicine Glaxo Wellcome Research and Development.
Introduction Integrative Analysis of Genomic Variants in Carcinogenesis Syed Haider, Arek Kasprzyk, Pietro Lio Artificial Intelligence and Computational.

Introduction Integrative Analysis of Genomic Variants in Carcinogenesis Syed Haider, Arek Kasprzyk, Pietro Lio Artificial Intelligence and Computational.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
3 rd Summer School in Computational Biology September 10, 2014 Frank Emmert-Streib & Salissou Moutari Computational Biology and Machine Learning Laboratory.

3 rd Summer School in Computational Biology September 10, 2014 Frank Emmert-Streib & Salissou Moutari Computational Biology and Machine Learning Laboratory.
A Framework for Biomarker and Surrogate Endpoint Use in Drug Development Janet Woodcock M.D. Acting Deputy Commissioner for Operations November 4, 2004.

A Framework for Biomarker and Surrogate Endpoint Use in Drug Development Janet Woodcock M.D. Acting Deputy Commissioner for Operations November 4, 2004.
Research & Innovation Horizon 2020 - societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 Health, demographic change and wellbeing

Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Duchenne Muscular Dystrophy: The Diagnostic Process.

Duchenne Muscular Dystrophy: The Diagnostic Process.
By: Logan Gillings, Reyes E. Cause Of Disease  Is a genetic disorder that causes progressive muscle weakness as individual muscle cells die.  An absence.

By: Logan Gillings, Reyes E. Cause Of Disease  Is a genetic disorder that causes progressive muscle weakness as individual muscle cells die.  An absence.
Diseases of the Pancreas November 19, 2007 NCDD Meeting Chair: Jane Holt Vice Chair: P. Jay Pasricha, MD.

Diseases of the Pancreas November 19, 2007 NCDD Meeting Chair: Jane Holt Vice Chair: P. Jay Pasricha, MD.
Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.

Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

Similar presentations

Ads by Google